Perspective Therapeutics (CATX) Change in Interest Receivables (2024 - 2026)
Perspective Therapeutics (CATX) reported Change in Interest Receivables of $392000.0 for Q1 2026, up 429.73% on a YoY basis from $74000.0 in Q1 2025, and up 340.49% sequentially from -$163000.0 in Q4 2025.
Perspective Therapeutics (CATX) Change in Interest Receivables (2024 - 2026) Analysis & Trends
Perspective Therapeutics (CATX) has 3 years of Change in Interest Receivables data on file, last reported at $392000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Interest Receivables rose 429.73% year-over-year to $392000.0; the trailing twelve-month figure through Mar 2026 stood at $460000.0 (down 51.78% YoY), and the FY2025 full-year result was $142000.0, down 83.86% from the prior year.
- Change in Interest Receivables improved to $392000.0 in Q1 2026, from -$163000.0 in the prior quarter.
- In the past five years, Change in Interest Receivables ranged from a high of $880000.0 in Q4 2024 to a low of -$163000.0 in Q4 2025.
- A 3-year average of $235666.7 and a median of $143000.0 in 2025 frame the typical range for Change in Interest Receivables.
- Across the five-year window, Change in Interest Receivables sank 118.52% in 2025 and soared 429.73% in 2026, its largest moves.
- Tracing CATX's Change in Interest Receivables over 3 years: stood at $880000.0 in 2024, then slumped by 118.52% to -$163000.0 in 2025, then soared by 340.49% to $392000.0 in 2026.
- Business Quant data shows CATX's Change in Interest Receivables at $392000.0 in Q1 2026, -$163000.0 in Q4 2025, and $19000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Interest Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | - |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | - |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | - |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Perspective Therapeutics | 146.05 Mn | 146.05 Mn | - | 392,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 392,000.00 |
| Dec 31, 2025 | -163,000.00 |
| Sep 30, 2025 | 19,000.00 |
| Jun 30, 2025 | 212,000.00 |
| Mar 31, 2025 | 74,000.00 |
| Dec 31, 2024 | 880,000.00 |